CPA
TMCI icon

Capital Performance Advisors’s Treace Medical Concepts TMCI Stock Holding History

Capital Performance Advisors’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$6 – 2452
2024
Q3 		$6 Buy
+1
New +$6 ﹤0.01% 2889

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Performance Advisors's TMCI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Treace Medical Concepts (TMCI) in Q4 2024, closing a stake of 1 share — an estimated $6 sold.

Capital Performance Advisors first reported a position in TMCI in Q3 2024 and held it in 1 quarter. The position peaked at $6 in Q3 2024. 135 funds tracked by Wall St. Rank hold TMCI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Treace Medical Concepts position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1 Treace Medical Concepts share in Q4 2024, an estimated $6.
  • Capital Performance Advisors first reported a position in Treace Medical Concepts in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Treace Medical Concepts position peaked at $6 in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.